[Should estrogen replacement therapy be applied in women with genital and breast cancer?].
In this country, hormone replacement therapy (HRT) has been used more extensively in the last few years. The benefits of HRT in cardiovascular diseases, osteoporosis and quality of life has been well established. Breast cancer and endometrial carcinoma have been considered as contraindications for HRT. A reappraisal of this practice is necessary since we have no evidence that HRT may adversely influence the outcome of these tumours. Nevertheless, theoretically this is possible because the effect of estrogens on occult metastases in unknown. The relationship between replacement therapy and the uterine sarcomas is of particular concern. HRT is safe in patients successfully treated for carcinoma of the vulva, vagina, uterine cervix and in those with ovarian cancer. Experience suggests that the estrogen can also be used safely in women treated previously for endometrial cancer. As far as breast cancer is concerned it appears logical to discuss the risk-benefit considerations with our patients before embarking on using HRT. Consultation with a gynaecological oncologist prior to HRT in patients with endometrial and/or breast cancer is strongly recommended.
Bösze
P
P
MAV Kórház, Szülészeti és Nögyógyászati Osztály, Budapest.
D000328:Adult; D001943:Breast Neoplasms; D000075202:Contraindications; D003657:Decision Making; D016889:Endometrial Neoplasms; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D005833:Genital Neoplasms, Female; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors
Adható-e hormonpótló kezelés a nöi nemiszervek és az emlök daganatainak eseteiben?